Will Johnson & Johnson (JNJ) Q2 Innovation Medicine revenue be above __?$16.35B
ResolvedOutcome: Yes$5Kas of
Odds now
This market has resolved Yes. Final market pricing put YES at 100%, as of .
YES100¢
NO0¢
as of
What moved the odds?
1 AI-matched news signals on this market, newest first. Entry price is the called side when the news hit; the signed return marks it against the final price as of .
$JNJ Johnson & Johnson Q2 2026 Earnings • -Adj EPS $2.90 (est $2.85) • -Sales $25.31B (est 25.04B) • -Medtech Sales $8.93b (est $8.99b) • -Medicine Revenue $16.38b (est $16.12b) • -Sees FY Sales $100.88 To $101.48, Saw $100.3b To $101.3b • -Sees FY Adj EPS $11.60 To $11.75, Saw $11.45 To $11.65 • Sees FY Sales $100.8b To $101.4b, Saw $100.3b To $101.3b
Where does the news lean?
2YES1NO0neutraltrailing 24h
Average match confidence across the listed signals: 99%.
Past moves on this market
Material odds moves (≥8 points within an hour of a matched news signal), newest first — each links to a dated brief on what moved the price.
How did this market resolve?
This market will resolve to "Yes" if Johnson & Johnson's Innovative Medicine revenue for the upcoming second fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Related markets
See all outcomes for Will Johnson & Johnson (JNJ) Q2 Innovation Medicine revenue be above __? — the full event, with combined odds and signal timeline.